Dehydrozingerone ameliorates renal structure compromised in diabetic nephropathy

Area of Science:

• Nephrology
• Metabolomics
• Molecular Biology

Background:

• Diabetes is a major risk factor for chronic kidney disease, but mechanisms are unclear.
• High-fat diet (HFD) induced diabetes leads to kidney dysfunction and renal injuries.
• Understanding molecular changes in diabetic kidneys is crucial for developing treatments.

Purpose of the Study:

• To investigate the long-term effects of HFD on mouse renal tissue using transcriptomic and proteomic analysis.
• To evaluate the potential of dehydrozingerone (DH) in ameliorating HFD-induced diabetic kidney disease.
• To elucidate the molecular mechanisms underlying kidney dysfunction and DH's therapeutic effects.

Main Methods:

• Transcriptomic and proteomic profiling of renal tissue from mice fed a high-fat diet (HFD) or normal diet (NCD), with or without dehydrozingerone (DH) treatment.
• Induction of diabetes in mice using HFD and streptozotocin (STZ).
• Assessment of kidney function through biochemical markers (albuminuria, proteinuria) and molecular analysis of protein and gene expression.

Main Results:

• HFD-induced diabetes caused significant kidney dysfunction, characterized by albuminuria, proteinuria, and altered blood serum markers.
• Renal injuries included defects in the glomerular filtration system, downregulation of transport and metabolic proteins, and impaired lipid metabolism.
• HFD feeding increased oxidative stress, induced mitochondrial dysfunction, activated apoptosis (BAX pathway), and triggered epigenetic alterations (HDAC1 activation).
• Dehydrozingerone (DH) treatment positively regulated transport systems, mitochondrial function, lipid metabolism, DNA damage, epigenetic alterations, and oxidative stress, ameliorating kidney function.

Conclusions:

• Long-term HFD feeding leads to complex molecular changes in the kidney, including impaired transport, lipid metabolism, increased oxidative stress, mitochondrial dysfunction, and epigenetic alterations.
• Dehydrozingerone (DH) demonstrates significant potential in mitigating HFD-induced diabetic kidney disease by reversing these detrimental molecular changes.
• DH represents a promising therapeutic agent for managing diabetic kidney disease, warranting further investigation.